European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/11/2026

1. ORCL
2. ADBE
3. RH
4. SPY
5. CPRT
6. ACVA
7. SEDG
8. SPCX
9. TLT
10. PMTS

Go back to European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
Merck & Co. (NYSE: MRK) Delayed: 144.40 -0.31 (0.21%)
Previous Close $144.71    52 Week High $65.46 
Open $145.52    52 Week Low $47.97 
Day High $145.90    P/E 98.23 
Day Low $143.82    EPS $1.47 
Volume 2,196,801